ClinicalTrialsFinder
RecruitingPhase 1NCT07223125

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors

Sponsor

Janssen Research & Development, LLC

Enrollment

360 participants

Start Date

Oct 10, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced-stage Solid Tumors

Summary

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
  • Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom

Exclusion Criteria5

  • Active central nervous system (CNS) involvement unless clinically stable
  • History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
  • History of solid organ or hematologic stem cell transplantation
  • Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
  • Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJNJ-89862175

JNJ-89862175 will be administered.

Locations(6)

AdventHealth Orlando

Orlando, Florida, United States

NEXT Oncology

Irving, Texas, United States

Centre Leon Berard

Lyon, France

Gustave Roussy

Villejuif, France

Severance Hospital Yonsei University Health System

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07223125